1. Home
  2. BCDA vs AMBO Comparison

BCDA vs AMBO Comparison

Compare BCDA & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • AMBO
  • Stock Information
  • Founded
  • BCDA N/A
  • AMBO 2000
  • Country
  • BCDA United States
  • AMBO United States
  • Employees
  • BCDA N/A
  • AMBO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • AMBO Other Consumer Services
  • Sector
  • BCDA Health Care
  • AMBO Real Estate
  • Exchange
  • BCDA Nasdaq
  • AMBO Nasdaq
  • Market Cap
  • BCDA 7.9M
  • AMBO 7.2M
  • IPO Year
  • BCDA N/A
  • AMBO 2010
  • Fundamental
  • Price
  • BCDA $2.32
  • AMBO $2.64
  • Analyst Decision
  • BCDA Strong Buy
  • AMBO
  • Analyst Count
  • BCDA 1
  • AMBO 0
  • Target Price
  • BCDA $25.00
  • AMBO N/A
  • AVG Volume (30 Days)
  • BCDA 52.0K
  • AMBO 127.9K
  • Earning Date
  • BCDA 03-26-2025
  • AMBO 12-30-2024
  • Dividend Yield
  • BCDA N/A
  • AMBO N/A
  • EPS Growth
  • BCDA N/A
  • AMBO N/A
  • EPS
  • BCDA N/A
  • AMBO N/A
  • Revenue
  • BCDA $71,000.00
  • AMBO $7,839,000.00
  • Revenue This Year
  • BCDA N/A
  • AMBO N/A
  • Revenue Next Year
  • BCDA N/A
  • AMBO N/A
  • P/E Ratio
  • BCDA N/A
  • AMBO N/A
  • Revenue Growth
  • BCDA N/A
  • AMBO N/A
  • 52 Week Low
  • BCDA $1.63
  • AMBO $1.00
  • 52 Week High
  • BCDA $8.85
  • AMBO $6.30
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 49.50
  • AMBO 56.53
  • Support Level
  • BCDA $2.12
  • AMBO $2.30
  • Resistance Level
  • BCDA $2.73
  • AMBO $2.90
  • Average True Range (ATR)
  • BCDA 0.23
  • AMBO 0.32
  • MACD
  • BCDA 0.01
  • AMBO 0.02
  • Stochastic Oscillator
  • BCDA 35.82
  • AMBO 79.00

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.

Share on Social Networks: